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SOLID PHASE ISOTHERMAL AMPLIFICATION
Technical field of the invention
The present invention relates t o an amplification technology for multiple, rapid,
sensitive, specific detection of nucleic acids in samples originating from the
environment, water, food, animals, plants, microorganisms, cell cultures, or
humans. I n particular, the present invention relates t o isothermal amplification
and detection of nucleic acids using a method called Solid Phase Loop Mediated
Amplification (SP-LAMP) including a solid support amplification step. The invention
also relates t o kits and uses of the method.
Background of the invention
Nucleic acid amplification technologies are presently utilized in a variety of very
different disciplines such as medicine, forensic science, research applications and
disease diagnostics. Disease may originate and spread from many different
habitats, including plants, microorganisms, animals, humans or food. As an
example, more than 200 known diseases are transmitted through foods or food
products. Despite recent advancement in food safety, developing countries are
still experiencing the burden of foodborne pathogenesis. I t is recognized that non-
typhoidal Salmonella spp, Campylobacter jejuni , verotoxin producing Escherichia
coli 0157: 1-17, Listeria monocytogenes and Shigella dysenteriae are the most
common foodborne pathogens. The globalized agro-food production is becoming
more and more elongated. Food moves across borders and continents in shorter
time frames. Consequently, contaminated foods have often been consumed before
authorities can react. Conventional culture methods or molecular-based methods
have been the main workhorses for food safety control; they are expensive, time-
consuming, require sample enrichment, sample preparation, target purification,
target amplification and comes with the inability for online testing.
Food safety is a major public health threat. For example, Salmonellosis, an
infectious disease caused by Salmonella spp. is one of the most common food
borne diseases worldwide. I t is estimated that there are at least 100,000
Salmonellosis cases per year in the EU countries, and approximately 1 million
cases in the United States. To date, the conventional bacterial culture method is
still used as gold standard for food safety control. The methods involve several
steps (pre-enrichment, selective enrichment, isolation in selective agar and
serological and biochemical confirmation) to obtain the result. The whole process
usually takes 5 t o 7 days t o be completed.
I n the last decade, molecular diagnostic methods such as polymerase chain
reaction (PC ) have been developed for the detection of pathogens (e.g.
Salmonella) in much shorter time. Although there are a number of effective
nucleic acid-based detection assays currently commercial available, many of them
often require tedious, costly, and time-consuming procedures. Furthermore, a
large number of these assays require multiple handling steps, which can adversely
affect the reliability of the results due to cross-contamination problems.
Frequently, low concentrations of the target nucleic acid molecule of interest
contribute t o the inability to detect the target nucleic acid molecule in the sample.
The development of the polymerase chain reaction (PCR) as a method for
amplifying nucleic acids in samples has revolutionized modern life sciences
research, and has improved the ability to develop sensitive and reliable nucleic
acid detection assays. However, the use of PCR is limited by the thermal
constrains. The PCR process needs an electrically powered thermal cycler with
precise three stages temperature control and a fast transition between stages,
which is usually accomplished by a bulky and power-intensive apparatus that is
not suitable for online and at point of need applications.
An alternative approach is the so-called isothermal amplification that has been
developed t o overcome the drawbacks of PCR. For this type of amplification, the
use of other polymerases allows nucleic acid amplification at constant and low
temperature. There are a number of different isothermal amplification techniques,
and among them, Loop-Mediated Isothermal Amplification (LAMP) (T. Notomi et
al., Nucleic Acid Res. (2000), Vol. 28, No. 12 e63 and WO00028082) has attracted
considerable interest due to its rapid amplification, simple operation, and high
sensitivity and specificity. LAMP is characterized by the use of four to six different
primers, specifically designed t o recognize six distinct regions on the target gene,
which makes it highly specific for its target even in the presence of high
concentration of non-target DNA. The process is performed at a constant
temperature {e.g. 60-65°C) using a strand displacement reaction, thus obviating
the demand for sophisticated thermal control. Fast and efficient amplification can
be achieved since there is no time required for temperature ramping during the
LAMP process. Owing to these advantages, the LAMP technology has been widely
applied for rapid detection of different pathogens such as Salmonella spp.,
Campylobacter spp., Escherichia coli, Staphylococcus aureus, etc. (L. Niessen et
al. Food Microbiol. (2013), 36, 191-206).
I n order to comply with the demands from consumers for safe, pathogen-free
food, there is an urgent need for development of a rapid and reliable method for
online or at site Salmonella detection. Adapting LAMP to Lab-on-a-chip (LOC)
systems seems to be a very promising approach for monitoring pathogen at point-
of-care (POC).
Hence, an improved method for establishing traceability of foodborne pathogens
in the entire food chain would be advantageous.
Summary of the invention
The Solid Phase Loop Mediated Amplification (SP-LAMP) method according to the
present invention provides a solid phase isothermal amplification technology, for
multiple, rapid, sensitive, specific detection of nucleic acid targets. Examples of
targets are foodborne pathogens, infectious diseases e.g. Salmonella spp.
Campylobacter spp., Listeria monocytogenes and Norovirus as well as cancer
markers or other diseases marker etc.). The targets may originate from e.g. from
the environment, food, animals or humans. The technique also poses a great
potential for easily integration into different format of Lab on-a-chip systems for
point of care. The novel SP-LAMP technique will open a great potential alternative
to the existing techniques for online rapid diagnostic, for not only detection and
identification of foodborne pathogens in food and animal production chains, but
also for health care, environmental, and many other fields with feasibility and field
applicability.
Thus, an object of the present invention relates to the provision of an alternative
LAMP amplification process involving a solid support amplification step.
In particular, it is a n object of the present invention to provide a method that
solves the above-mentioned problems of the prior art with point-of-care detection
in e.g. a lab-on-a-chip format.
Thus, one aspect of the invention relates to a loop mediated isothermal
amplification (LAMP) method for detecting a n oligonucleotide target sequence
comprising:
a ) providing a sample suspected of comprising a n oligonucleotide target
sequence, said oligonucleotide target sequence comprising in the 3' to 5'
direction:
a n F3C region, complementary to a n F3 region;
a n F2C region, complementary to a n F2 region;
a n F1C region, complementary to a n Fl region;
IV a spacer region;
v a Bl region, complementary to a B1C region;
v i a B2 region, complementary to a B2C region; and
vii a B3 region complementary to a B3C region;
providing a primer A (modFIP) comprising in the 5' to 3' direction
i . a PI region, complementary to a PIC region;
ii. a n F1C region, complementary to the Fl region; and
iii. a n F2 region, complementary to the F2C region;
and/or
providing a primer B (FIP) comprising in the 5' to 3' direction:
iv. a n F1C region, complementary to the Fl region; and
v. a n F2 region, complementary to the F2C region;
providing a primer C (BIP) comprising in the 5' to 3' direction:
i . a detection label;
ii. a B1C region, complementary to the Bl region; and
iii. a B2 region, complementary to the B2C region;
and/or
providing a primer D (modBIP) comprising in the 5' to 3' direction
iv. a detection label;
v . a blocking region;
vi. a B1C region, complementary to the Bl region; and
vii. a B2 region, complementary to the B2C region;
with the proviso that if both primer C (BIP) and primer D (modBIP) are
provided, then only one of primer C (BIP) and primer D (modBIP)
comprises a detection label according to step (c)(i) and step (c)(iv),
respectively;
d) providing a primer E (F3), complementary to the F3C region;
e) providing a primer F (B3), complementary to the B3C region;
f) providing a solid phase coupled primer G (SP-primer) comprising a free 3'-
end and having an immobilization region being complementary to a region
of the oligonucleotide target sequence or a LAMP product arising from the
oligonucleotide target sequences;
g) mixing the sample according to step a) and primers according to step b)-f)
with a LAMP amplification mixture, thereby providing an amplified LAMP
product coupled to the solid support if a target sequence is present in the
sample;
h) optionally, washing the solid support; and
i) detecting the amplified product coupled to the solid support, by detecting
the detection label, e.g. by fluorescence.
Another aspect of the present invention relates to a kit comprising :
- Primers according to the present invention;
- An amplification mixture according to the present invention; and
- Optionally, instructions for detecting the presence or absence of a
defined target sequence using the primer set and amplification
mixture of the kit.
Yet another aspect of the present invention relates to the use of a kit according to
the present invention for the detection of a target sequence.
Brief description of the figures
Figure 1 shows the design of the primers in the scenario when F3, B3, FIP and BIP
primers are used together with modFIP.
Figure 2-9 show the liquid phase (LP) steps of the present invention.
Figure 2A-C show conversion of LP-1A t o LP-2A and LP-3A.
Figure 3A-D show conversion of LP-2A to LP-4A and LP-5A.
Figure 4A-G show conversion of LP-3A t o LP-3G, LP-6A, LP-7A and LP-8A.
Figure 5A-H show conversion of LP-6A to LP-6C1, LP-6G, LP-9A, LP-10A and LP-
11A.
Figure 6 show conversion of LP-7A to LP-2A and LP-7B.
Figure 7A-B show conversion of LP-8A to LP-4A, LP-8B and LP-12B.
Figure 8A-B show conversion of LP-9A to LP-2A and LP-9C
Figure 9A-D show conversion of LP-6C1 t o LP-4A, LP-6C3 and LP-13C
Figure 10 shows a summary of the nucleic acid amplification in the liquid phase
(LP). The amplification products termed LP-4A is further amplified on the solid
phase (SP).
Figure 11A-B show the solid phase (SP) steps of the present invention for the
amplification product termed LP-4A. The F2C region of LP-4A anneal t o the F2
region of SP-1 t o form SP-2. The strand is extended (SP-3) to form the final
amplification product SP-4.
Figure 12 shows detection of Salmonella Spp. utilizing the SP-LAMP method.
Lanes termed FIP, FIP21 and FIP22 contains target solid phase (SP) primers which
are designed to target products in the liquid phase. The FIP solid phase primer
(F2=20 bp) is the same as the FIP primer except for the 10T10C linker. FIP 21
has a longer binding region (F2 +15bp extended). FIP 22 has a much longer
binding region (F2+29 bp extended). Primers in the liquid phase are designed
based on a conserved region of hilA gene sequences of Salmonella Enteritidis and
was used to target Salmonella species. All solid phase primers (HIP, FIP, FIP21
and FIP22) and Cy5 control probes were attached on the COC surface and then
the LAMP master-mix (MX1, MX2 or MX3) was added. After amplification, the COC
slide was washed and scanned. The Cy5 control probe is an oligo 10T IOC which
was labelled with Cy5 at 5' end and served as positive control both in the spotting
process and the SP-LAMP reaction. The HIP solid phase primer is designed based
on the hipO gene sequences of Campylobacter jejuni - unrelated to Salmonella
spp. The HIP solid phase primer was used as negative control in the SP-LAMP.
Figure 13A-B show (A) a schematic representation of the experimental setup. Cy5
represents a Cy5 control probe, which served as positive control. HIP is a solid
phase primer targeting Campylobacter jejuni. I t is used in this experiment as
negative control. SP1, SP2 and SP3 are solid phase primers of different lengths,
which are designed to target Listeria monocytogenes. (B) shows arrayed locations
in which solid phase amplification as fluorescent dots.
Figure 14A-B show (A) gel electrophoresis visualization of the SP-LAMP
amplification products of AIV of different subtypes as sampled from embryonated
chicken eggs. AIV subtype is denoted in the top of each lane. Location and date of
virus collection is denoted in the bottom of each lane. NDV is an abbreviation for
Newcastle Disease Virus - a non-AIV sample used as a control. CN is a control
negative test. (B) shows gel electrophoresis visualization of the SP-LAMP (left) or
T-PC (right) amplification products of AIV in infected wild-bird samples
collected in Denmark.
The present invention will now be described in more detail in the following.
Detailed description of the invention
Definitions
Prior to discussing the present invention in further details, the following terms and
conventions will first be defined :
Sample
In the present context, the term "sample" refers to any biological solution, entity
or subject. This can include, but is not limited to, solutions from the environment
or food as well as organisms, biological fluids, tissues, organs, e.g. humans or
mammals and all of their body parts. The sample may contain organisms or a
specific cell type within an organism, e.g. a cell overexpressing a gene of interest.
An example of such a sample may be a sample derived from food containing an
organism of interest that bears a characteristic gene sequence or oligonucleotide
sequence.
Oligonucleotide
In the present context, the term "oligonucleotide" refers to a sequence of DNA or
RNA (including micro RNA (miRNA) and messenger RNA (mRNA)) nucleotides
residues or any nucleotide analogue thereof that form a molecule.
Oligonucleotides can bind their complementary sequences to form duplexes
(double-stranded fragments) or even fragments of a higher order.
Oligonucleotides can be on a linear form, but also exist as circular oligonucleotide
molecules, such as single stranded circular RNAs or single-stranded circular DNAs.
When referring the length of a sequence, reference may be made to the number
of nucleotide units or to the number of bases.
Furthermore, the typical DNA or RNA nucleotides may be replaced by nucleotides
analogues such as 2'-0-Me-RNA monomers, 2'-0- alkyl-RNA monomers, 2'-amino-
DNA monomers, 2'-fluoro-DNA monomers, locked nucleic acid (LNA) monomers,
arabino nucleic acid (ANA) monomers, 2'-fluoro-ANA monomers, 1,5-
anhydrohexitol nucleic acid (HNA) monomers, peptide nucleic acid (PNA), and
morpholinoes.
Target sequence
In the present context, the term "target sequence" refers to an oligonucleotide
sequence of interest that is desired to detect. The target sequence is typically
representative of an organism of interest and may be detected by amplification
using the method of the present invention, which result in large amounts of the
target sequence labelled with a detection label, such as a fluorophore.
The target sequence may comprise regions (F3C, F2C, FIC, Bl, B2 and B3)
complementary to the primers according to the method of the invention. The
primers used in the method of the present invention may be designed specifically
to detect a target sequence of interest. Theoretically, it is therefore possible to
detect any target sequence with a known sequence.
Typically, the target sequence is comprised of RNA or DNA residues and originates
from a n organism of interest, such as a pathogenic organism.
Primer
In the present context, the term "primer" refers to a nucleic acid sequence that
serves as a starting point for DNA synthesis. It is required for DNA replication
because the enzymes that catalyse this process, DNA polymerases, can only add
new nucleotides to an existing strand of DNA. The polymerase starts replication at
the 3'-end of the primer, and copies the opposite strand.
In the present context, primers are specifically designed to target a target
sequence of interest and to work according to the method of the present
invention. Thus depending on the function of the primer, the length of the primer
may vary from 10 nucleotides to as much as 100 nucleotides.
Spacer region
In the present context, the term "spacer region" refers to an oligonucleotide
region of the target sequence that is located in between the F3C, F2C, FIC regions
and the Bl, B2, B3 regions of the target sequence. Thus, the spacer region is
located downstream from F3C, F2C, FIC regions and upstream from Bl, B2, B3
regions when reading in the 3' to 5' direction.
The spacer region may be comprised of any sequence of oligonucleotides, such as
a non-functional part of a genome, an entire gene or a part of a gene.
Blocking region
In the present context, the term "blocking region" refers to an oligonucleotide
region of the modBIP primer according to the present invention. The purpose of
the blocking region is to prevent self-primed DNA synthesis activity of the strand,
so the product LP-4A can be stable immobilized on the solid surface.
Thus, the blocking region of the modBIP primer catalyzes the generation of stem
loop primers (LP-4A) without self-primed DNA synthesis activity in the liquid
phase.
The blocking region may comprise any sequence of nucleotides that prevent self-
primed DNA synthesis activity. Thus, the blocking region may be designed
specifically to be suitable for use with any target sequence.
Solid phase/solid support
In the present context, the terms "solid phase" and "solid support" are used
interchangeably and relates to a solid material. This solid material may be formed
from one or more insoluble or a substantially insoluble materials, which materials
may be inorganic or organic, which materials are chemically inert (or substantially
chemically inert) with respect to the reagents and conditions used in the method
of the present invention.
Examples of inorganic materials include, but are not limited to glass, silica, porous
glass, aluminosilicate, borosilicate and metal oxides (for example, aluminium
oxide, nickel oxide, and iron oxide).
The solid support may also be formed from an organic polymeric material, which
polymeric material is optionally crosslinked. Examples of organic polymeric
materials include, but are not limited to, cellulose (from different sources, e.g.
plants, insects, bacteria etc.), polysaccharide, crosslinked polysaccharides,
polystyrene, crosslinked polystyrene, polyacryloylmorpholide, polyamide resin,
polyacryloyl pyrollidone, polyethylene, polyethylene glycol, crosslinked
polyethylene glycol, poly(vinyl acetate), poly(methyl methacrylate),
poly(dimethylsiloxane), poly(methacrylic acid), polycarbonate, polyethylene
terephthalate, polypropylene, poly(ethylenoxide), poly(lactic acid), polypropylene
copolymer, polyacrylonitrile, cyclic olefin copolymer, cyclic olefin polymer,
polyethylene glycol-polystyrene, polystyrene, cross-linked dextran, and/or cross-
linked agarose.
The solid support may be in any suitable form, including but not limited to resins,
particles, beads, fibres and films.
In the present invention, the solid phase primer (SP-primer) may be coupled to
the solid support by e.g. A) physical absorption (e.g. on amine, nitrocellulose,
poly(l-lysine, PAAH, or diazonium ion surface); B) chemisorption (e.g. thiols-
gold); C) covalent immobilization (e.g. amines, amino, or hydrazide-modified DNA
oligo nucleotides on carboxyl (with carbodiimide), aldehyde, isothiocyanate, or
epoxide modified surfaces, hydrazide disulphide coupling, thiols-maleimide, thiol-
mercaptosilane, thiols-acrylamide etc.); or D) affinity-binding (e.g. avidin-biotin,
streptavidin-biotin). Amongst option C) is coupling via a poly(T)10-poly(C)10 tail
(TC tag). Other lengths and ratios of T and C combinations are also applicable. TC
tags may be linked onto a solid support by UV light irradiation. The coupling of the
SP-primer onto the solid support enables amplification on the solid support.
The present solid-phase amplification is a method in which molecules are bound
on a solid support and amplification is performed in a reactant solution. Compared
with normal amplification in a liquid state, it is easier to remove excess reactant
or by-product from the product.
Detection label
In the present context, the term "detection label" refers to a molecular entity,
which may be used to detect the amplified target sequence following amplification
according to the method of the present invention.
The readout of the detection label may be based on a technique including, but not
limited to, fluorescence, chemiluminescence, radioactivity, magnetism, turbidity,
phosphorescence, colorimetric, chemical labelling {e .g. silver), Surface Plasmon
Resonance (SPR), and refractive index.
The detection label may be detected by a method selected from the group
consisting of microscopy, (micro) array scanners, fluorescence microscopy,
fluorescence spectroscopy, Fluorescence-activated cell sorting (FACS), NMR,
spectroscopy, optical detectors, CCD cameras and scanners.
In the present invention, it is preferred that the detection label is selected from
the group consisting of a fiuorophore or a radioiabei. Fiuorophores include, but are
not limited to, synthetic fiuorophores, fluorescent proteins, quantum dots,
intercalating dyes and scorpion dyes. In the present context, the terms
"fiuorophore" and "dye" are used interchangeably.
As described above, a n object of the present invention relates to the provision of
a n alternative LAMP amplification process involving a solid support amplification
step.
Thus, a n aspect of the present invention relates to a loop mediated isothermal
amplification (LAMP) method for detecting a n oligonucleotide target sequence
comprising:
a ) providing a sample suspected of comprising a n oligonucleotide target
sequence, said oligonucleotide target sequence comprising in the 3' to 5'
direction:
i . a n F3C region, complementary to a n F3 region;
ii. a n F2C region, complementary to a n F2 region;
iii. a n F1C region, complementary to a n Fl region;
iv. a spacer region;
v . a Bl region, complementary to a B1C region;
vi. a B2 region, complementary to a B2C region; and
vii. a B3 region complementary to a B3C region;
b) providing a primer A (modFIP) comprising in the 5' to 3' direction:
i . a PI region, complementary to a PIC region;
ii. a n F1C region, complementary to the Fl region; and
iii. an F2 region, complementary to the F2C region;
and/or
providing a primer B (FIP) comprising in the 5' t o 3' direction:
iv. an F1C region, complementary to the Fl region; and
v . an F2 region, complementary to the F2C region;
providing a primer C (BIP) comprising in the 5' to 3' direction:
i . a detection label;
ii. a B1C region, complementary to the Bl region; and
iii. a B2 region, complementary to the B2C region;
and/or
providing a primer D (modBIP) comprising in the 5' t o 3' direction
iv. a detection label;
v . a blocking region;
vi. a B1C region, complementary to the Bl region; and
vii. a B2 region, complementary to the B2C region;
with the proviso that if both primer C (BIP) and primer D (modBIP) a
provided, then only one of primer C (BIP) and primer D (modBIP)
comprises a detection label according to step (c)(i) and step (c)(iv),
respectively;
d) providing a primer E (F3), complementary to the F3C region;
e) providing a primer F (B3), complementary to the B3C region;
f) providing a solid phase coupled primer G (SP-primer) comprising a free 3'-
end and having an immobilization region being complementary to a region
of the oligonucleotide target sequence or a LAMP product arising from the
oligonucleotide target sequences;
g) mixing the sample according to step a) and primers according to step b)-f)
with a LAMP amplification mixture, thereby providing an amplified LAMP
product coupled to the solid support if a target sequence is present in the
sample;
h) optionally, washing the solid support; and
i) detecting the amplified product coupled to the solid support, by detecting
the detection label, e.g. by fluorescence.
The SP-LAMP method provides a rapid and reliable method for online or at site
detection of any target sequence. It is especially advantageous that the solid-
phase amplification is a method in which molecules are bound on a solid support
because amplification products can be easily purified by removal of excess
reactants or by-products from the product. This purification is more tedious using
a liquid state amplification setup.
The method is outlined in example 1 and figures 1-11, which illustrates the liquid
phase and solid phase amplification of the SP-LAMP process using the primers F3,
B3, FIP, BIP, modFIP and SP-primer. The SP-LAMP is also applicable using other
combinations of primers. The F3 and B3 are always present. However, the SP-
LAMP method may be carried out with other combinations as given below:
a) with only normal primers FIP and BIP {i.e. without modified primers, see
MX1 data in example 2)
b) with only modified primers {i.e. with modFIP and modBIP)
c) with all "normal" and modified primers {i.e. with FIP, BIP, modFIP and
modBIP, see MX3 data in example 2)
d) with "cross-combinations" of "normal" and modified primers, i.e. ;
with FIP and modBIP
with FIP, modFIP and modBIP
with FIP, BIP, modFIP (as outlined in example 1, see MX2 data in
example 2)
IV. with FIP, BIP, modBIP
v . with BIP and modFIP
V I . witth BIP, modBIP and modFIP
The method as described herein functions also in a multiplex setup for detection
of multiple target sequences out of a single sample. For multiplex detection, a
solid surface comprising an array of a multitude of different solid phase coupled
primers is provided and the corresponding primer sets according to the method is
mixed with a sample and added t o the solid surface. I n the multiplex setup, solid
phase primers and the corresponding primer set (e.g. combination of F3, B3, FIP,
BIP, modFIP and modBIP) is designed specifically for the target sequence of
interest. Therefore, the method can be used for identifying a multiple of different
infectious species out of a single sample. Thus, in an embodiment of the
invention, the sample is added t o a surface comprising an array of a multitude of
different solid phase coupled primers and mixed with primer sets corresponding t o
the target sequences of interest.
Therefore, the method as described herein may be used t o detect simultaneously,
in a single sample, target sequences originating from a multitude of different
species, including, but not limited to, Salmonella spp, Campylobacter jejuni,
verotoxin producing Escherichia coli 0157: 1-17, Listeria monocytogenes, Shigella
dysenteriae, Avian influenza Virus and NoroVirus.
The target sequence of the SP-LAMP method is defined by seven regions (F3C,
F2C, F1C, a spacer region, Bl, B2 and B3 in the 3' t o 5' direction). These regions
may in theory be assigned t o any oligonucleotide sequence of interest, making it a
target sequence. Thus, the seven regions of the target sequence are "fictional" in
that they are assigned t o the target sequence and the entire set of SP-LAMP
primers are designed t o function with the assigned regions.
The length of the each of the seven regions may vary depending o n the selection
of target sequence.
Thus, an embodiment of the present invention relates t o the method as described
herein, wherein the F3C region, complementary t o a F3 region, has a length of
10-30 nucleotides, such as 15-25, o r such as 20-25.
Another embodiment of the present invention relates t o the method as described
herein, wherein the F2C region, complementary t o a F2 region, has a length of
10-30 nucleotides, such as 15-25 o r such as 20-25.
Yet another embodiment of the present invention relates to the method as
described herein, wherein the FIC region, complementary to a Fl region, has a
length of 10-30 nucleotides, such as 15-25, or such as 20-25.
The spacer region is located in between the F3C, F2C, FIC regions and the Bl, B2,
B3 regions of the target sequence. This spacer region may be comprised of any
sequence of oligonucleotides, such as a non-functional part of a genome, an entire
gene or a part of a gene.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the spacer region in the target sequence, has a length of 1-500
nucleotides, such as 1-200 nucleotides, such as 1-100 nucleotides, or such as 5-
100 nucleotides.
Another embodiment of the present invention relates to the method as described
herein, wherein the Bl region, complementary to a B1C region, has a length of
10-30 nucleotides, such as 15-25 or such as 20-25.
A further embodiment of the present invention relates to the method as described
herein, wherein, the B2 region, complementary to a B2C region, has a length of
10-30 nucleotides, such as 15-25, or such as 20-25.
A still further embodiment of the present invention relates to the method as
described herein, wherein the B3 region, complementary to a B3C region, has a
length of 10-30 nucleotides, such as 15-25, or such as 20-25.
To ensure that amplified products are immobilized on the solid support in order to
undergo solid phase LAMP, the solid phase primer (primer G) is designed to
comprise an immobilization region, which is complementary to a region of the
original target sequence.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the immobilization region, complementary to a region of the
oligonucleotide target sequence, has a length of 10-30 nucleotides, such as 15-25
or such as 20-25.
I n some variants of the present invention, but not all, the LAMP master-mixture
comprises a modFIP primer. The modFIP primer is defined by three regions (PI,
F1C and F2 in the 5' t o 3' direction). The nucleotide composition of the modFIP
primer is decided upon after selection of a target sequence. Thus, the modFIP
primer is custom designed to, amongst other, complement the Fl and F2C regions
of the target sequence. I n addition to the F1C and F2 regions, the modFIP primer
also comprise a PI region, which leads to the formation of liquid state
amplification products, LP-4A, comprising a complementary PIC region. The PIC
region of LP-4A may then in turn anneal to the solid phase coupled primer (SP
primer), which shares the PI region with the modFIP primer.
Since the PI region of the modFIP primer is not complementary to any region of
the target sequence, the design of the PI region is independent of the selection of
target sequence. Consequently, the PI region may be designed to obtain the
optimal conditions for efficient solid phase amplification. I n any event, the length
and composition of nucleotides of the PI region may vary to obtain the best
interplay with the remaining SP-LAMP primer set.
Depending on the nucleotide composition of the target sequence, the total length
of the modFIP and FIP primers may vary.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the primer A (modFIP), has a length of 40-100 nucleotides, such
as 40-80 nucleotides, or such as 40-70 nucleotides.
Another embodiment of the present invention relates to the method as described
herein, wherein the primer B (FIP), has a length of 40-100 nucleotides, such as
40-80 nucleotides, or such as 40-70 nucleotides.
I n some variants of the present invention, but not all, the LAMP master-mixture
comprises a modBIP primer.
The modBIP primer comprises three regions and a detection label (detection label,
blocking region, B1C and B2 in the 5' to 3' direction). The purpose of the blocking
region of modBIP is t o prevent self-primed DNA synthesis activity and generation
of a stem loop primer (LP-4A) without self-primed DNA synthesis activity in the
liquid phase. The LP-4A products will then anneal to the solid phase coupled
primer to initiate solid phase amplification of the target sequence.
Similar to the PI region of the modFIP primer, the blocking region of modBIP is
independent of the target sequence in that it is designed to be non-
complementary to the target sequence. Therefore, the blocking region may
comprise any sequence of nucleotides that prevent self-primed DNA synthesis
activity. The length and composition of nucleotides of the blocking region may
vary to obtain the best interplay with the remaining SP-LAMP primer set.
Therefore, an embodiment of the present invention relates to the method as
described herein, wherein the blocking region in the primer D (modBIP) has a
length of 5 to 25 nucleotides, or such as 5 to 15 nucleotides.
Depending on the nucleotide composition of the target sequence, the total length
of the modBIP and BIP primers may vary.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the primer C (BIP), has a length of 40-100 nucleotides, such as
40-80 nucleotides, or such as 40-70 nucleotides.
Another embodiment of the present invention relates to the method as described
herein, wherein the primer D (modBIP), has a length of 40-100 nucleotides, such
as 40-80 nucleotides, or such as 40-70 nucleotides.
The F3 and B3 primers are classical primers in the sense that they are only
complementary to a single region of the target sequence with no nucleotide
overhang. The design of the F3 and B3 primers is completely dependent on the
target sequence. Depending on the nucleotide composition of the target sequence,
the length of the F3 and B3 primers may vary.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the primer E (F3), has a length of 10-30 nucleotides, such as 15-
25.
Another embodiment of the present invention relates to the method as described
herein, wherein the primer F (B3), has a length of 10-30 nucleotides, or such as
15-25.
The function of the solid phase coupled primer (SP primer) is three-fold {i.e.
attachment, annealing, synthesis). First, the SP-primer must be attachable to a
solid support. Second, the SP-primer must have a n immobilization region being
complementary to a region of the oligonucleotide target sequence or a LAMP
product arising from the oligonucleotide target sequences. In one embodiment of
the present invention, the immobilization region of the SP-primer is a PI region to
which the stem loop primer (LP-4A) without self-primed DNA synthesis activity
can anneal. DNA synthesis is initiated subsequent to the stem loop primer (LP-4A)
annealing to the SP-primer. Thus, the PI region of the SP-primer serves a dual
purpose. As described above, the PI region of the SP-primer is identical to the PI
region of the modFIP primer and the length and composition of nucleotides of the
PI region may vary to obtain the best interplay with the remaining SP-LAMP
primer set.
Therefore, a n embodiment of the present invention relates to the method as
described herein, wherein the solid phase coupled primer G (SP-primer) has a
length of 10-200 nucleotides, such as 15-150, such as 20-100, such as 25-80 or
such as 30-50 nucleotides.
In a n embodiment of the present invention, the PI region of the SP-primer is
replaced with a n F2 region, which is complementary to the F2C region. Thus, the
stem loop primer (LP-4A) without self-primed DNA synthesis activity anneal to the
SP-primer via the F2C region of LP-4A.
As the modBIP or BIP primers are designed to comprise a detectable label, all LP-
4A products also comprise a detectable label by virtue of the method. After
completion of the SP-LAMP amplification of the target sequence it is therefore
possible to determine the presence or absence of the target sequence.
The readout of the detection label may be based on any technique that does not
interfere with the SP-LAMP method and include, but is not limited to,
fluorescence, radioactivity and magnetism.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the detection label of the primer C (BIP) and/or the primer D
(modBIP) is selected from the group consisting of a fluorophore and a radiolabel.
Fluorophores include, but are not limited to, synthetic fluorophores, fluorescent
proteins, quantum dots, intercalating dyes and scorpion dyes.
For detection of the amplification product, it is possible to use fluorescent labels
that suits the experimental setup with respect to photostability, excitation
wavelength, emission wavelength etc.
Fluorophores suitable as detection label for the amplification product of the
present invention include, but are not limited to, the ones listed in table 1 .
Table 1 : List of Fluorophores with details of characteristic (Excitation wavelength,
emission wavelength and visible colour)
Dye name Excitation Emission Visible colour
Wavelength (nm) wavelength (nm)
Hydrocoumarin 325 386 Blue
Methoxycoumarin 360 410 Blue
Alexa Fluor 350 346 442 Blue
Aminocoumarin 350 445 Blue
Cy2 490 510 Green (dark)
FAM 495 516 Green (dark)
Alexa Fluor 488 495 519 Green (light)
Fluorescein FITC 495 518 Green (light)
Alexa Fluor 430 434 539 Green (light)
Alexa Fluor 532 531 554 Green (light)
HEX 535 556 Green (light)
Cy3 550 570 Yellow
T ITC 547 572 Yellow
Alexa Fluor 546 556 573 Yellow
Alexa Fluor 555 555 565 Yellow
R-phycoerythrin (PE) 480; 565 578 Yellow
Rhodamine Red-X 560 580 Orange
Tamara 565 580 Red
Cy3.5 581 581 596 Red
Rox 575 602 Red
Alexa Fluor 568 578 603 Red
Red 613 480; 565 613 Red
Texas Red 561 594 Red
Alexa Fluor 594 590 617 Red
Alexa Fluor 633 632 647 Red
Allophycocyanin 650 660 Red
Alexa Fluor 647 650 668 Red
Cy5 650 670 Red
Alexa Fluor 660 663 690 Red
Cy5.5 675 694 Red
TruRed 490; 675 695 Red
Alexa Fluor 680 679 702 Red
Cy7 743 770 Red
Other suitable dyes include Tetrachlorofluorescein (TET), SYBR green I or II, YBR
Green II, SYBR Gold, YO (Oxazole Yellow), TO (Thiazole Orange) and PG
(PicoGreen).
Furthermore, an embodiment of the present invention relates to the method as
described herein, wherein the fluorophore is selected from the group consisting of
Hydrocoumarin, Methoxycoumarin, Alexa Fluor, Aminocoumarin, Cy2, FAM, Alexa
Fluor 488, Fluorescein FITC, Alexa Fluor 430, Alexa Fluor 532, HEX, Cy3, TRITC,
Alexa Fluor 546, Alexa Fluor 555, R-phycoerythrin (PE), Rhodamine Red-X,
Tamara, Cy3.5 581, Rox, Alexa Fluor 568, Red 613, Texas Red, Alexa Fluor 594,
Alexa Fluor 633, Allophycocyanin, Alexa Fluor 633, Cy5, Alexa Fluor 660, Cy5.5,
TruRed, Alexa Fluor 680, Cy7, tetrachlorofluorescein (TET), SYBR green I or II,
YBR Green II, SYBR Gold, YO (Oxazole Yellow), TO (Thiazole Orange) and PG
(PicoGreen).
A preferred embodiment of the present invention, relates to the method as
described herein, wherein the fluorophore is Cy5.
The SP-primer is designed so that it may be coupled to a solid support. Such
coupling may be based on either covalent or non-covalent interactions between
the SP-primer and the solid support. Such non-covalent interactions include, but
are not limited to, hydrophobic interactions, electrostatic/ionic interactions, van
der Waals interactions and the like.
The SP-primer may be attached to the solid support by UV treatment, wherein a
covalent bond is formed between a TC tail and a plain and unmodified solid
surface. Thus, an target oligo with a poly(T)10-poly(C)10 tail can be immobilised
by UV irradiation at 254 nm with power of 3 mW/cm 2 for 10 min (Stratalinker
2400, Stratagene, CA, USA) on a plain and unmodified solid surface.
Alternative methods for coupling the solid phase primer (SP-primer) to the solid
support include, but are not limited to A) physical absorption (e.g. on amine,
nitrocellulose, poly(l-lysine, PAAH, or diazonium ion surface); B) chemisorption
(e.g. thiols-gold); C) covalent immobilization (e.g. amines, amino, or hydrazide-
modified DNA oligo nucleotides on carboxyl (with carbodiimide), aldehyde,
isothiocyanate, or epoxide modified surfaces, hydrazide disulphide coupling,
thiols-maleimide, thiol-mercaptosilane, thiols-acrylamide etc.); or D) affinity-
binding (e.g. avidin-biotin, streptavidin-biotin). Amongst option C) is coupling via
a poly(T)10-poly(C)10 tail (TC tag). Other lengths and ratios of T and C
combinations are also applicable. TC tags may be linked onto a solid support by
UV light irradiation. The coupling of the SP-primer onto the solid support enables
amplification on the solid support.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the solid phase coupled primer G (SP-primer) comprises a 5'
linker sequence, supporting coupling to the solid support.
The solid support may be comprised of any material that do not interact non-
specifically with the nucleotide material. A list of suitable materials is given in the
definitions section. The solid support may consist of a single material or a
combination of two or more materials.
An embodiment of the present invention relates to the method as described
herein, wherein the solid phase coupled primer G (SP-primer) is coupled to a solid
support selected from the group consisting of a glass slide, a cover slip, COC
(cyclic olefin copolymer), COP (cyclic olefin polymer), PS (polystyrene), PC
(polycarbonate), PMMA (poly(methyl methacrylate)), PDMS
(poly(dimethylsiloxane)), PET (poly(ethylene terephthalate)), cellulose-based
beads, sheet or paper, a glass bead, a polymeric bead, a nanobead, a
nanoparticle, graphene, an ELISA plate, and a polymeric multiple well plate.
Furthermore, the solid support may be in any suitable form, including but not
limited to resins, particles, beads, fibres, DNA structures (DNA origami) and films.
The SP-LAMP method includes not only a sample and suitable primers for
amplification thereof, but also LAMP amplification mixture that is mixed with the
sample and the primer set. The amplification mixture comprises all the building
blocks necessary for nucleotide amplification (strand elongation) and suitable
polymerase enzymes to facilitate the amplification.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the LAMP amplification mixture of step g) comprises at least one
polymerase enzyme supporting LAMP amplification and dinucleotide triphosphates
(dNTPs).
Another embodiment of the present invention relates to the method as described
herein, wherein the polymerase enzyme, has strand displacement activity.
The term strand displacement describes the ability to displace downstream DNA
encountered during synthesis. Some polymerase enzymes has strand
displacement activity and are active at moderate temperatures, around 20-37°C.
Other polymerase enzymes, such as BST polymerase, has strand displacement
activity and are active at elevated temperatures, around 65°C. In the present
invention, it is preferred t o utilize polymerase enzymes that work at elevated
temperatures.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the polymerase enzyme is selected from the group consisting of
Bst polymerase, Bst DNA Polymerase Large Fragment, Bsm DNA Polymerase, Bsu
DNA Polymerase Large Fragment, SD DNA Polymerase, Deep VentR DNA
Polymerase, Deep VentR TM (exo) DNA Polymerase, DNA Polymerase I Large
(Klenow) Fragment, M-MuLV Reverse Transcriptase, Phi29 DNA Polymerase, VentR
DNA Polymerase, VentR (exo) DNA Polymerase, StrandDisplace Thermostable DNA
Polymerase, and combinations thereof.
The SP-LAMP method also encompass amplification of RNA target sequences. I n
that case, it is necessary to convert the RNA target sequence t o DNA. This process
is called reverse transcription and is mainly associated with retroviruses. The
active enzyme in the process is called reverse transcriptase.
Therefore, an embodiment of the present invention relates to the method as
described herein, wherein the LAMP amplification mixture further comprises a
reverse transcriptase, such as an AMV reverse transcriptase.
An advantage of the SP-LAMP method is that it is performed at isothermal
conditions, meaning that the temperature is not cycled as in classical PCR. This
circumvents the need for an advanced electrically powered thermal cycler with
precise three stages temperature control and a fast transition between stages.
With the SP-LAMP method, amplification may be adapted to lab-on-a-chip (LOC)
or lateral flow systems that allows monitoring pathogens onsite with only the need
for a container capable of maintaining a constant temperature.
Therefore, an embodiment of the present invention relates to the method as
described herein, wherein the amplification steps are performed at a temperature
in the range between 30-75°C, such as 40-70°C, such as 50-65°C, or such as 55-
65°C.
Since the primer set may be specifically designed for any given target sequence,
said target sequence may be any nucleotide sequence from double-stranded DNA
to single-stranded genomic NA.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the target sequence is single-stranded or double-stranded.
Another embodiment of the present invention relates to the method as described
herein, wherein the target sequence is DNA or RNA.
The sample may be selected for any source from which amplification of a target
sequence is desired. In a preferred embodiment of the present invention, the
sample is suspected to contain a pathogen.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the sample is selected from the group consisting of food
(liquid/solid and semi solid), feed (liquid/solid and semi solid), blood (serum,
buffer coat, treated with heparin or EDTA), tissue (paraffin embedded), tumor,
biopsy, sputum, swabs (from both human and animal), fecal (from both human
and animal), water and waste-water samples.
Swabs may be from cloacal, surface or skin of human or animal, but may also be
of non-living origin such as from other solid surfaces, e.g. from tables and metal
or rubber chains in production lines.
Target sequences may be selected from any pathogen of interest. However, the
method also applies to non-pathogenic target sequences, wherein amplification is
desired.
Therefore, an embodiment of the present invention relates to the method as
described herein, wherein the target sequence is of pathogenic origin, such as of
bacterial, fungi or viral origin, or from a gene involved in a disease.
Another embodiment of the present invention relates to the method as described
herein, wherein the target sequence originates from an organism selected from
the group consisting of Salmonella spp, Campylobacter jejuni, verotoxin producing
Escherichia coli 0157: 1-17, Listeria monocytogenes, Shigella dysenteriae, Avian
Influenza Virus and Norovirus.
A further embodiment of the present invention relates t o the method as described
herein, wherein the target sequence is a salmonella sequence.
The immobilization region is a region of the solid phase coupled primer, which is
complementary t o any region of the target sequence. I n one embodiment, the
immobilization region preferably comprises an F2 region.
Thus, an embodiment of the present invention relates t o the method as described
herein, wherein the immobilization region comprises an F2 region, complementary
t o an F2C region.
Another embodiment of the present invention relates t o the method as described
herein, wherein the F2 region of the immobilization region has a length of at least
10 nucleotides, such as at least 20 nucleotides, such as at least 30 nucleotides,
such as at least 4 0 nucleotides, such as at least 50 nucleotides.
The modFIP primer comprises a PI region, which may be used as binding partner
for the immobilization region of the solid phase coupled primer.
Therefore, an embodiment of the present invention relates t o the method as
described herein, wherein the method comprises providing a primer A (modFIP).
Another embodiment of the present invention relates t o the method as described
herein, wherein the immobilization region of the primer G is complementary t o a
PIC region.
I n contrast t o traditional LAMP amplification in solution, the method of the present
invention is suitable for simultaneous detection of multiple target sequences out of
a single sample.
Thus, an embodiment of the present invention relates to the method as described
herein, wherein the method comprises primers for detection of multiple target
sequences.
The constituents of the SP-LAMP method may be packed in an easy to use kit that
comprise all the necessary parts {i.e. primers, amplification mixture, instructions
etc.) to perform amplification of a single target sequence. In a preferred
embodiment of the invention, the kit comprises parts suitable for SP-LAMP
amplification of a pathogen.
Thus, another aspect of the present invention relates to a kit comprising:
- Primers according to the present invention;
- An amplification mixture according to the present invention; and
- Optionally, instructions for detecting the presence or absence of a
defined target sequence using the primer set and amplification
mixture of the kit.
A kit as described herein may also contain multiple sets of primers that allow
detection of multiple target sequences, e.g. from different pathogenic species.
Therefore, an embodiment of the present invention relates to the kit as described
herein, wherein primers for detection of multiple target sequences are included.
Another embodiment of the present invention relates to the kit as described
herein, which is suitable for use in a lab-on-a-chip (LOC) or lateral flow format.
Still another aspect of the present invention relates to the use of a kit as
described herein for the detection of a target sequence.
Another embodiment of the present invention relates to the use as described
herein, wherein multiple targets are detected simultaneously in a single sample.
It should be noted that embodiments and features described in the context of one
of the aspects of the present invention also apply to the other aspects of the
invention.
Items
Item 1 . A loop mediated isothermal amplification (LAMP) method for detecting an
oligonucleotide target sequence comprising :
a) providing a sample suspected of comprising an oligonucleotide target
sequence, said oligonucleotide target sequence comprising in the 3' to 5'
direction:
i . an F3C region, complementary to an F3 region;
ii. an F2C region, complementary to an F2 region;
iii. an F1C region, complementary to an Fl region;
iv. a spacer region;
v . a Bl region, complementary to a B1C region;
vi. a B2 region, complementary to a B2C region; and
vii. a B3 region complementary to a B3C region;
b) providing a primer A (modFIP) comprising in the 5' to 3' direction:
i . a PI region, complementary to a PIC region;
ii. an F1C region, complementary to the Fl region; and
iii. an F2 region, complementary to the F2C region;
and/or
providing a primer B (FIP) comprising in the 5' to 3' direction:
iv. an F1C region, complementary to the Fl region; and
v. an F2 region, complementary to the F2C region;
providing a primer C (BIP) comprising in the 5' to 3' direction:
i . a detection label;
ii. a B1C region, complementary to the Bl region; and
iii. a B2 region, complementary to the B2C region;
and/or
providing a primer D (modBIP) comprising in the 5' to 3' direction
iv. a detection label;
v . a blocking region;
vi. a B1C region, complementary to the Bl region; and
vii. a B2 region, complementary to the B2C region;
with the proviso that if both primer C (BIP) and primer D (modBIP) are
provided, then only one of primer C (BIP) and primer D (modBIP)
comprises a detection label according to step (c)(i) and step (c)(iv),
respectively;
d) providing a primer E (F3), complementary to the F3C region;
e) providing a primer F (B3), complementary to the B3C region;
f) providing a solid phase coupled primer G (SP-primer) comprising a free 3'-
end and having an immobilization region being complementary to a region
of the oligonucleotide target sequence or a LAMP product arising from the
oligonucleotide target sequences;
g) mixing the sample according to step a) and primers according to step b)-f)
with a LAMP amplification mixture, thereby providing an amplified LAMP
product coupled to the solid support if a target sequence is present in the
sample;
h) optionally, washing the solid support; and
i) detecting the amplified product coupled to the solid support, by detecting
the detection label, e.g. by fluorescence.
Item 2 . The method according to item 1, wherein the F3C region, complementary
to an F3 region, has a length of 10-30 nucleotides, such as 15-25, or such as 20-
25.
Item 3 . The method according to items 1 or 2, wherein the F2C region,
complementary to an F2 region, has a length of 10-30 nucleotides, such as 15-25
or such as 20-25.
Item 4 . The method according to any one of the preceding items, wherein the FIC
region, complementary to an Fl region, has a length of 10-30 nucleotides, such
as 15-25, or such as 20-25.
Item 5 . The method according to any one of the preceding items, wherein the
spacer region in the target sequence, has a length of 1-500 nucleotides, such as
1-200 nucleotides, such as 1-100 nucleotides, or such as 5-100 nucleotides.
Item 6 . The method according to any one of the preceding items, wherein the Bl
region, complementary to a B1C region, has a length of 10-30 nucleotides, such
as 15-25 or such as 20-25.
Item 7 . The method according to any one of the preceding items, wherein, the B2
region, complementary to a B2C region, has a length of 10-30 nucleotides, such
as 15-25, or such as 20-25.
Item 8 . The method according to any one of the preceding items, wherein the B3
region, complementary to a B3C region, has a length of 10-30 nucleotides, such
as 15-25, or such as 20-25.
Item 9 . The method according to any one of the preceding items, wherein the
immobilization region, complementary to a region of the oligonucleotide target
sequence, has a length of 10-30 nucleotides, such as 15-25 or such as 20-25.
Item 10. The method according to any one of the preceding items, wherein the
primer A (modFIP), has a length of 40-100 nucleotides, such as 40-80
nucleotides, or such as 40-70 nucleotides.
Item 11. The method according to any one of the preceding items, wherein the
primer B (FIP), has a length of 40-100 nucleotides, such as 40-80 nucleotides, or
such as 40-70 nucleotides.
Item 12. The method according to any one of the preceding items, wherein the
primer C (BIP), has a length of 40-100 nucleotides, such as 40-80 nucleotides, or
such as 40-70 nucleotides.
Item 13. The method according to any one of the preceding items, wherein the
primer D (modBIP), has a length of 40-100 nucleotides, such as 40-80
nucleotides, or such as 40-70 nucleotides.
Item 14. The method according to any one of the preceding items, wherein the
blocking region in the primer D (modBIP) has a length of 5 to 25 nucleotides, or
such as 5 to 15 nucleotides.
Item 15. The method according to any one of the preceding items, wherein the
primer E (F3), has a length of 10-30 nucleotides, such as 15-25.
Item 16. The method according to any one of the preceding items, wherein the
primer F (B3), has a length of 10-30 nucleotides, or such as 15-25.
Item 17. The method according to any one of the preceding items, wherein the
solid phase coupled primer G (SP-primer) has a length of 10-200 nucleotides,
such as 15-150, such as 20-100, such as 25-80 or such as 30-50 nucleotides.
Item 18. The method according to any one of the preceding items, wherein the
detection label of the primer C (BIP) and/or the primer D (modBIP) is selected
from the group consisting of a fluorophore and a radiolabel.
Item 19. The method according to item 18, wherein the fluorophore is selected
from the group consisting of Hydrocoumarin, Methoxycoumarin, Alexa Fluor,
Aminocoumarin, Cy2, FAM, Alexa Fluor 488, Fluorescein FITC, Alexa Fluor 430,
Alexa Fluor 532, HEX, Cy3, TRITC, Alexa Fluor 546, Alexa Fluor 555, R-
phycoerythrin (PE), Rhodamine Red-X, Tamara, Cy3.5 581, Rox, Alexa Fluor 568,
Red 613, Texas Red, Alexa Fluor 594, Alexa Fluor 633, Allophycocyanin, Alexa
Fluor 633, Cy5, Alexa Fluor 660, Cy5.5, TruRed, Alexa Fluor 680, Cy7,
tetrachlorofluorescein (TET), SYBR green I or II, YBR Green II, SYBR Gold, YO
(Oxazole Yellow), TO (Thiazole Orange) and PG (PicoGreen).
Item 20. The method according to item 19, wherein the fluorophore is Cy5.
Item 21. The method according to any one of the preceding items, wherein the
solid phase coupled primer G (SP-primer) comprises a 5' linker sequence,
supporting coupling to the solid support.
Item 22. The method according to any one of the preceding items, wherein the
solid phase coupled primer G (SP-primer) is coupled to a solid support selected
from the group consisting of a glass slide, a cover slip, COC (cyclic olefin
copolymer), COP (cyclic olefin polymer), PS (polystyrene), PC (polycarbonate),
PMMA (poly(methyl methacrylate)), PDMS (poly(dimethylsiloxane)), PET
(poly(ethylene terephthalate)), cellulose-based beads, sheet or paper, a glass
bead, a polymeric bead, a nanobead, a nanoparticle, graphene, an ELISA plate,
and a polymeric multiple well plate.
Item 23. The method according to any one of the preceding items, wherein the
LAMP amplification mixture of step g) comprises at least one polymerase enzyme
supporting LAMP amplification and dinucleotide triphosphates (dNTPs).
Item 24. The method according to item 23, wherein the polymerase enzyme, has
strand displacement activity.
Item 25. The method according to items 23 or 24 wherein the polymerase enzyme
is selected from the group consisting of Bst polymerase, Bst DNA Polymerase
Large Fragment, Bsm DNA Polymerase, Bsu DNA Polymerase Large Fragment, SD
DNA Polymerase, Deep VentR DNA Polymerase, Deep VentR TM (exo) DNA
Polymerase, DNA Polymerase I Large (Klenow) Fragment, M-MuLV Reverse
Transcriptase, Phi29 DNA Polymerase, VentR DNA Polymerase, VentR (exo) DNA
Polymerase, StrandDisplace Thermostable DNA Polymerase, and combinations
thereof.
Item 26. The method according to any one of items 23-25, wherein the LAMP
amplification mixture further comprises a reverse transcriptase, such as an AMV
reverse transcriptase.
Item 27. The method according to any one of the preceding items, wherein the
amplification steps are performed at a temperature in the range between 30-
75°C, such as 40-70°C, such as 50-65°C, or such as 55-65°C.
Item 28. The method according to any one of the preceding items, wherein the
target sequence is single-stranded or double-stranded.
Item 29. The method according t o any one of the preceding items, wherein the
target sequence is DNA o r NA .
Item 30. The method according t o any one of the preceding items, wherein the
sample is selected from the group consisting of food (liquid/solid and semi solid),
feed (liquid/solid and semi solid), blood (serum, buffer coat, treated with heparin
or EDTA), tissue (paraffin embedded), tumor, biopsy, sputum, swabs (from both
human and animal), fecal (from both human and animal), water and waste-water
samples.
Item 31. The method according t o any one of the preceding items, wherein the
target sequence is of pathogenic origin, such as of bacterial, fungi or viral origin,
o r from a gene involved in a disease.
Item 32. The method according t o item 31, wherein the target sequence
originates from an organism selected from the group consisting of Salmonella spp,
Campylobacter jejuni , verotoxin producing Escherichia coli 0157: 1-17, Listeria
monocytogenes, Shigella dysenteriae, Avian Influenza Virus and Norovirus.
Item 33. The method according t o any one of the preceding items, wherein the
target sequence is a salmonella sequence.
Item 34. The method according t o any one of the preceding items, wherein the
immobilization region comprises an F2 region, complementary t o an F2C region.
Item 35. The method according t o item 34, wherein the F2 region of the
immobilization region has a length of at least 10 nucleotides, such as at least 20
nucleotides, such as at least 30 nucleotides, such as at least 4 0 nucleotides, such
as at least 50 nucleotides.
Item 36. The method according t o any one of the preceding items, wherein the
method comprises providing a primer A (modFIP).
Item 37. The method according t o item 36, wherein the immobilization region of
the primer G is complementary t o a PIC region.
Item 38. The method according to any one of the preceding items, wherein the
method comprises primers for detection of multiple target sequences.
Item 39. A kit comprising :
- Primers according to item 1;
- An amplification mixture according to items 23-26; and
- Optionally, instructions for detecting the presence or absence of a
defined target sequence using the primer set and amplification
mixture of the kit.
Item 40. The kit according to item 39, wherein primers for detection of multiple
target sequences are included.
Item 41. The kit according to any one of items 39 or 40, suitable for use in a lab-
on-a-chip (LOC) or lateral flow format.
Item 42. Use of a kit according to any one of items 39-41 for the detection of a
target sequence.
Item 43. The use according to item 42, wherein multiple targets are detected
simultaneously in a single sample.
All patent and non-patent references cited in the present application, are hereby
incorporated by reference in their entirety.
The invention will now be described in further details in the following non-limiting
examples.
Examples
Example 1: Overall strategy of the Solid Phase Loop Mediated
Amplification (SP-LAMP) method
Without being bound by theory, the following example illustrates how SP-LAMP is
performed. Thus, the SP-LAMP method may be performed in variants related to
the setup described in the following example. I n this example, the SP-LAMP
technology is exemplified when using the F3, B3, FIP, BIP and modFIP primers.
The SP-LAMP technology consists of two phases of amplification - the liquid phase
amplification and the solid phase amplification. I n the text below, we use the term
"conventional LAMP" for the existing LAMP technology to differentiate the known
art from the new SP-LAMP technology developed in this invention. It is noted that
the liquid phase amplification and the solid phase amplification can be performed
simultaneously as illustrated in e.g. claim 1 or in separate steps that may be
separated in time and/or space.
Primer design
For SP-LAMP, two primer pairs and one modFIP were used (F3/B3, FIP/BIP and
modFIP). Two primer pairs F3/B3 and FIP/BIP were designed as conventional
LAMP primers, whereas the modFIP primer was equal t o a FIP primer with an
oligonucleotide added to the 5' end (Figure 1). The BIP primer was labelled with a
Cy5 fluorophore at the 5' end. The two pairs of primers and modFIP were used in
the liquid phase to produce stem loop primers labelled with Cy5 (LP-4A, see Fig
3D) and without self-primed DNA synthesis activity. These products (LP-4A)
served as the target for SP-primer binding and immobilisation on the solid phase.
LP-4A does not exist in conventional LAMP.
A FIP SP-primer was designed t o include an oligonucleotide repeat (10T10C) at
the 5' end. The 10T10C sequence was used to link the SP-primer t o the solid
phase by UV treatment. LP-4A products from the liquid phase annealed t o the
solid phase primer to initiate the SP-LAMP amplification.
The liquid phase (LP) steps of the amplification
I n the LAMP reaction of the conventional LAMP technology, the LAMP primers
anneal to the complementary sequence on a double stranded target DNA (LP-IA,
figure 2A) at 65°C and initiate the DNA synthesis using DNA polymerase with
strand displacement activity. First, two pairs of primers (F3/B3 and FIP/BIP, figure
2A) were used t o form a stem loop primer (LP-1B, figure 2A). This stem loop
primer (mentioned in the conventional LAMP technology) has self-priming DNA
synthesis activity at the 3' end and continuously acts to form a double strand at
the B2 loop of the stem loop. Secondly, the F2 region of modFIP anneal to the F2C
region of LP-1C (figure 2B) and synthesize the complimentary strand;
simultaneously releasing a loop at 3' end (LP-1D, figure 2B). Self-priming DNA
synthesis activity at 3' end of LP-1D continues and releases LP-2A and LP-3A
(figure 2C).
I n LP-2A, simultaneously self-primed DNA synthesis activity at 3' end of LP-2A
(Fig 3A), the B2 region of BIP labelled with Cy5 annealed to B2C of LP-2A and
synthesized the complementary strand (LP-2B, Fig3A). These activities led to the
release of a loop at the 3' end (LP-2B2, Fig3B). The LP-2B2 does not have a self-
priming DNA synthesis activity due to the blocking region (PIC) at the 3' end.
Thus, the F2 region of modFIP can anneal to the F2C region at the 3' end of LP-
2B2 and synthesis (LP-2C), leading to the release of a stem loop without self-
priming DNA synthesis activity and with a Cy5 label at the 5' end (LP-4A) and of
LP-5A (Fig 3C). LP-5A is a dead product because there is not any loop/position for
primer annealing to start amplification. LP-4A can be used as template for the FIP
SP-primer.
Continuing with LP-3A, this product has a loop containing a B2C region that the
B2 region of BIP-Cy5 annealed to (LP-3B, Fig 4A) and synthesized the other
complementary strand, simultaneously releasing two loops (LP-3C, Fig 4B). The
LP-3C has two loops with self-priming DNA synthesis activity at free 3' end. This
activity leads t o release LP-6A (Fig 4C). Simultaneously, the B2 region of BIP
anneal to the B2C region on the loop of LP-3D (Fig 4C) and synthesizes a
complementary strand to form LP-3E with four loops (Fig 4D). LP-3E has two
loops with B2C and F2C regions, which BIP and modFIP can anneal to and
synthesize new strands (LP-3F, Fig 4E). Simultaneously with activity of the BIP
and modFIP, self-priming DNA synthesis at 3' end of LP-3F continuously acts to
release LP-7A, LP-8A and LP-3G (Fig 4F and Fig 4G). LP-3G in Fig 4F continues
working to form more and more loops.
On the LP-6A, the self-priming DNA synthesis activity and BIP act together (Fig
5A) to release LP-6C (Fig 5B) with two loops and a self-priming DNA synthesis at
the 3' end. modFIP anneals to a loop containing a F2C region and synthesizes a
new strand (LP-6C, Fig 5B). Simultaneously, the self-priming DNA synthesis acts
and releases LP-9A, LP-6C1 and LP-6D (Fig 5C and Fig 5D). LP-6D has a loop
containing a B2C region that BIP can anneal to (LP-6E, Fig 5D) and synthesize LP-
6F (Fig 5E) with more loops. Primers modFIP and BIP continues annealing to those
loops (LP-6F, Fig 5E), simultaneously self-priming DNA synthesis activity and
release LP-10A (Fig 5F), LP-11A (Fig 5G) and LP-6G (Fig 5H). LP-6G in Fig 5H
continues working to form more and more loops.
Products contain a self-priming DNA synthesis at 3' end and multiple loops
including LP-7A (five loops), LP-8A (six loops), LP-9A (three loops), LP 6C1 (four
loops), LP-10A (five loops), LP-11A (eight loops), LP-12A (three loops) and LP-
13A (three loops). Those loops are positions for modFIP and BIP primers
annealing and synthesis of new strands. Simultaneously self-priming DNA activity,
they generate three types of products: LP-4A labeled with Cy5 (Fig 7B, Fig 9D)
which serve as template for solid phase amplification, dead products (without any
loops) such as LP-12B (Fig 7B) and LP-13C (Fig 9D), and products with single loop
or multiple loops such as LP-2A (Fig 6 and Fig 8B), LP-7B (Fig 6), LP-8B (Fig 7A),
LP-9C (Fig 8B), LP-6C3 (Fig 9B). Those products continue to synthesize new
strands since their loops are positions to which primers may anneal and elongate
strands.
The entire network of the liquid phase amplification part of the method is
schematically represented in figure 10.
The solid phase (SP) steps of the amplification
The stem loop primers without self-primed DNA synthesis activity from liquid
phase (LP-4A) served as starting materials for the solid phase amplification. The
F2C region of the stem loop primers annealed to the F2 region of the immobilized
solid phase primer (SP-1) on the surface (SP-2) (figure 11A) and synthesis of the
complementary strand (SP-3) lead to formation of a double strand with a Cy5-
label (SP-4) (figure 11B).
The above steps are purely included for illustrative purposes and in practice other
products may also be formed. The division into liquid phase and solid phase is also
only for illustrative purposes, since in practice the two phases are performed
simultaneously.
Detection of amplification product
A scanner may be used t o detect the presence of immobilised product (SP-4) on
the solid surface through the fluorescent Cy5 label. The slides may be scanned
using a BioAnalyzer 4F/4S scanner with 5000-ms shutter time (LaVision BioTec
GmbH, Bielefeld, Germany).
This example outlines the SP-LAMP process using a single combination of primers
{i.e. F3, B3, FIP, BIP, modFIP and SP-primer). As described herein, the SP-LAMP
process is also applicable using other combinations of primers (e.g. see example
2)
Example 2 : Detection of Salmonella spp by SP-LAMP with different
combinations of primers
Aim:
To verify that SP-LAMP can be used t o amplify and detect small amounts of target
DNA. I n this example, the primers were designed base on the hilA gene sequence
of Salmonella to target DNA originates from Salmonella spp. The PrimerExplorer
V4 (Eiken Chemical Co. Ltd, Tokyo, Japan) was used t o designed all the primers
based on hilA gene sequence from Salmonella Enteritica subsp. Enteritica serova
Newport (NCBI GenBank accession no. CP010. 280. 1). The primers then were
aligned for the specificity on NCBI website.
Methods:
SP-LAMP was performed as described in example 1, with primers and solid phase
primers designed according to table 2 . The solid phase primers including FIP,
FIP21 and FIP22 with poly(T)10-poly(C)10 tail was prepared at 60 µΜ
concentration in 5X SSC buffer, 0.04% Triton X and spotted on the COC slide
using non-contact array nano-plotter 2 .1 (GeSim, Dresden, Germany) with a
volume of 0.06 nL per spot. The COC slide was allowed to dry at room
temperature and then solid phase primers were immobilized on the COC surface
by exposing to the UV irradiation at 254 nm with power of 3 mW/cm 2 for 5 min
(Stratalinker 2400, Stratagene, CA, USA). During UV treatment, a covalent bond
was formed between TC tail and unmodified surface. Subsequently, the COC slide
was washed with 0.1X standard saline citrate (SSC) for 5 min then rinsed with
deionized water and dried in room temperature. BSA (bovine serum albumin) (2.5
mg/mL) covered all spots for 30 min to block the surface. The slide then was
rinsed in deionized water and dried in room temperature. A gene frame (Life
Technologies Europe BV, Danmark) was used t o cover all spots.
SP-LAMP was demonstrated with three different master-mixtures. All the master-
mixtures contained all components for the LAMP reaction. Master-mix 1 (MX1)
contained only normal primers F3, B3 FIP, and BIP. Master-mix 2 (MX2) contained
normal primers (F3, B3 FIP, and BIP) and only one modification primer, modFIP.
Master-mix 3 (MX3) contained normal primers (F3, B3 FIP, and BIP) and both
modification primers, modFIP and modBIP. Details of MX1, MX2 and MX3 are
given in tables 3-5.
25 uL of each master-mix was added to each gene frame as described above.
After 60 min (for MX1 and MX2) or 90 min (for MX3) of amplification at 65 °C, the
COC slide was washed for 5 min in washing solution containing 0 .1X standard
saline citrate (SSC) and 0 .1% (w/v) sodium dodecyl sulfate (SDS) for 5 min then
rinsed with deionized water for 2 min and dried in room temperature. The slide
then was scanned 1000ms with Cy5 filter by a BioAnalyzer 4F/4S scanner with
5000-ms shutter time (LaVision BioTec GmbH, Bielefeld, Germany).
Table 2
Name Sequences Size bp
F3 CGC ATA CTG CGA TAA TCC CTT C (SEQ I D NO: 1) 22
B3 ATT CTG TCG GAA GAT AAA GAG C (SEQ I D NO: 2) 22
CGC CGC AAC CTA CGA CTC ATA CTG CAG ACT
FIP 43
CTC GGA TTG AAC C (SEQ ID NO: 3)
GGC GGA GAC ACC ACT ACG ACC GTT ACA TTG
BIP 42
AAA CAC TGT ACG (SEQ I D NO: 4)
mod FIP AGT AGG ACC TAC ACC TGT CAC GCC GCA ACC 63
TAC GAC TCA TAC TGC AGA CTC TCG GAT TGA
ACC (SEQ I D NO :5)
mod BIP Cy5- CGG ATT GAA CGG CGG AGA CAC CAC TAC 52
GAC CGT TAC ATT GAA ACA CTG TAC G (SEQ ID
NO :6)
I I I I I I I I I 1CC CCC CCC CC C GCC GCA ACC
FIP SP-primer TAC GAC TCA TAC TGC AGA CTC TCG GAT TGA 63
ACC (SEQ I D NO :7)
I I I I I I I I I I C CCC CCC CCC GCC GCA ACC IAC
FIP2 1 SP-primer GAC TCA TAC TGC AGA CTC TCG GAT TGA ACC 78
TGA TCC TGC ATC TGA (SEQ I D NO :8)
I I I I I I I I I I C CCC CCC CCC GCC GCA ACC IAC
GAC TCA TAC TGC AGA CTC TCG GAT TGA ACC
FIP22 SP-primer 88
TGA TCC TGC ATC TGA AAA GGA AGT A (SEQ ID
NO :9)
The com ponents of the experiment were m ixed accord ing to tables 3-5 .
Table 3
Master-mix 1 (MX 1) without mod ification primers.
Table 4
Master-mix 2 (MX2) with modification FIP primers.
Table 5
Master-mix 3 (MX3) with both modification FIP and modificcation BIP primers.
Each of the master-mixtures (MX1, MX2 and MX3) according to tables 3-5,
respectively, was utilized together with three different solid phase (SP) primers
according to SEQ ID NOs: 7-9 (see table 2).
Results:
Figure 12 shows the SP-LAMP result. Cy5 represents a Cy5 control probe, which
served as positive control. HIP is a solid phase primer targeting Campylobacter
jejuni. It is used in this experiment as negative control. FIP, FIP21 and FIP22 are
solid phase primers of different lengths, which are designed to target Salmonella
spp. The result shows that all mixtures, MX 1, MX2 and MX3, containing the SP-
LAMP primers yielded bright fluorescent spots indicating that solid phase
amplification took place. I n contrast, spots containing the control HIP solid phase
primer originating from Campylobacter jejuni displayed no fluorescence. The data
shows that the SP-LAMP reaction, as designed in this experiment, is specific for
Salmonella. A Cy5 control probe served as a positive control.
Short conclusion:
The results show that SP-LAMP can successfully specifically amplify and detect
small amounts of DNA, while ignoring non-target DNA.
Example 3 : Detection of Listeria monocytogenes, Norovirus,
Campylobacter jejuni and Avian influenza virus by SP-LAMP
Aim:
To verify that SP-LAMP can be used t o amplify and detect small amounts of target
DNA from a variety of distinct and unrelated species.
Methods:
SP-LAMP was performed as described in example 1, with primers and solid phase
primers designed for detection of Listeria monocytogenes, Norovirus,
Campylobacter jejuni or Avian influenza virus. The experiments were carried out
as described in example 2 . Below is given the sequences utilized for detection of
Listeria monocytogenes. Master mixes (MX1-3) were mixed according to tables 3-
5 .
Table 6
Each of the master-mixtures (MX1, MX2 and MX3) according to tables 3-5,
respectively, was utilized together with three different solid phase (SP) primers
(SP1-3) according to SEQ ID NOs: 16-18 (see table 6).
Furthermore, LAMP primer sets were designed for detection of Avian influenza
virus (AIV). Sequences for detection of AIV are given in table 7 . The solid phase
primer (SP primer) was spotted on a COP slide. The remaining primers were
mixed according to table 8, the SP-LAMP reaction was run and the resulting
amplification products were determined by electrophoresis. The SP-LAMP results
were compared to detection by standard reverse-transcriptase PCR (RT-PCR).
Detection of AIV was tested in embryonated chicken eggs and wild-bird samples
collected in Denmark.
Table 7
Table 8
Components Stock cone. l x Final cone.
F3 (Mm) 20 0 .1 0.2 Mm
B3 (Mm) 20 0 .1 0.2 Mm
FIP (Mm) 100 0 .16 1.6 Mm
BIP-Cy5 (Mm) 100 0 .16 1.6 Mm
dNTPs (mM) 12.5 1 . 12 1.4 m M
Betaine (M) 2.5 2 0.5 Mm
Buffer (X) 10 1 l x
H20 2.34
Bst 2.0 warmstart (U) 0.5 0.4 U/ µ Ι
DNA (ng/ML) 2 1
Results:
Results similar to those obtained in example 2 (figure 12) were obtained for each
of the different species {i.e. Listeria monocytogenes, Norovirus, Campylobacter
jejuni or Avian influenza virus), data shown for Listeria monocytogenes and Avian
influenza virus (AIV).
Figure 13 shows the SP-LAMP result. Figure 13A shows a schematic representation
of the experimental setup. Cy5 represents a Cy5 control probe, which served as
positive control. HIP is a solid phase primer targeting Campylobacter jejuni. It is
used in this experiment as negative control. SP1, SP2 and SP3 are solid phase
primers of different lengths, which are designed to target Listeria monocytogenes.
Figure 13B shows that all mixtures, MX 1, MX2 and MX3, containing the SP-LAMP
primers yielded bright fluorescent spots indicating that solid phase amplification
took place. I n contrast, spots containing the control HIP solid phase primer
originating from Campylobacter jejuni displayed no fluorescence. The data shows
that the SP-LAMP reaction, as designed in this experiment, is specific for Listeria
monocytogenes. A Cy5 control probe served as a positive control.
Figure 14A demonstrates that the SP-LAMP method successfully detects AIV
growth in embryonated chicken eggs. The non-AIV sample (Newcastle Disease
Virus, NDV) and control negative test (CN) gives rise t o no signal. The figure
shows that the SP-LAMP method is capable of detecting different subtypes of AIV,
see HA and NA subtype designation in figure 14A.
Moreover, figure 14B shows that the SP-LAMP method successfully detects AIV in
infected wild birds samples collected in Denmark. The SP-LAMP method performed
better than the EU standard test relying on reverse-transcriptase PCR (RT-PCR),
demonstrating one of the advantages of the SP-LAMP method.
Short conclusion:
The results show that SP-LAMP can successfully specifically amplify and detect
targets of different species. The method is therefore suitable for detection of a
variety of different infectious or undesired species in a sample.
Example 4 : Multiplex detection of different targets
Aim:
To verify that SP-LAMP can be used t o amplify and detect simultaneously small
amounts of target DNA from a variety of distinct and unrelated species.
Methods:
SP-LAMP was performed as described in example 1 . Primers and solid phase
primers was designed for detection of Salmonella, Listeria monocytogenes,
Campylobacter jejuni, Campylobacter coli or Avian influenza virus. The solid phase
primers of these species were spotted and conducted in the same experiment. The
master-mix contained primers of all of these species. This experiment was carried
out as described in example 2 .
Results:
I n all cases, the Cy5 positive control showed fluorescence signal. When only
Salmonella DNA was added, fluorescence signal was observed only in spots where
the Salmonella SP-primer was spotted, whereas no fluorescence signal were
detected for other spots in which SP-primers from other bacterial or virus were
located, data not shown.
Similar results were obtained when DNA from the other pathogens (Listeria
monocytogenes, Campylobacter jejuni, Campylobacter coli or Avian influenza
virus) were added, data not shown.
When Salmonella DNA and Listeria Monocytogenes DNA were added
simultaneously, fluorescence signal were observed in spots containing either
Salmonella or Listeria Monocytogenes SP-primers, whereas no fluorescence signal
were detected for other spots in which SP-primers from other bacterial or virus
were located, data not shown.
When the master-mix contained all DNA targets of Salmonella, Listeria
monocytogenes, Campylobacter jejuni, Campylobacter coli or Avian influenza
virus, fluorescence signal were observed in all spots where the SP-primers
corresponded to any of these species, data not shown.
Short conclusion:
The results show that SP-LAMP can simultaneously and specifically amplify and
detect multiple targets of different species.
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Claims
1. A loop mediated isothermal amplification (LAMP) method for detecting an
oligonucleotide target sequence comprising :
a) providing a sample suspected of comprising an oligonucleotide target
sequence, said oligonucleotide target sequence comprising in the 3' to 5'
direction:
an F3C region, complementary to an F3 region;
an F2C region, complementary to an F2 region;
an F1C region, complementary to an Fl region;
iv. a spacer region;
v . a Bl region, complementary to a B1C region;
vi. a B2 region, complementary to a B2C region; and
vii. a B3 region complementary to a B3C region;
b) providing a primer A (modFIP) comprising in the 5' to 3' direction:
i . a PI region, complementary to a PIC region;
ii. an F1C region, complementary to the Fl region; and
iii. an F2 region, complementary to the F2C region;
and/or
providing a primer B (FIP) comprising in the 5' to 3' direction:
iv. an F1C region, complementary to the Fl region; and
v. an F2 region, complementary to the F2C region;
providing a primer C (BIP) comprising in the 5' to 3' direction:
i . a detection label;
ii. a B1C region, complementary to the Bl region; and
iii. a B2 region, complementary to the B2C region;
and/or
providing a primer D (modBIP) comprising in the 5' to 3' direction
iv. a detection label;
v . a blocking region;
vi. a B1C region, complementary to the Bl region; and
vii. a B2 region, complementary to the B2C region;
with the proviso that if both primer C (BIP) and primer D (modBIP) are
provided, then only one of primer C (BIP) and primer D (modBIP)
comprises a detection label according t o step (c)(i) and step (c)(iv),
respectively;
providing a primer E (F3), complementary to the F3C region;
providing a primer F (B3), complementary to the B3C region;
providing a solid phase coupled primer G (SP-primer) comprising a free 3'-
end and having an immobilization region being complementary t o a region
of the oligonucleotide target sequence or a LAMP product arising from the
oligonucleotide target sequences;
mixing the sample according to step a) and primers according to step b)-f)
with a LAMP amplification mixture, thereby providing an amplified LAMP
product coupled t o the solid support if a target sequence is present in the
sample;
h) optionally, washing the solid support; and
detecting the amplified product coupled to the solid support, by detecting
the detection label, e.g. by fluorescence.
2 . The method according to claim 1, wherein the detection label of the primer C
(BIP) and/or the primer D (modBIP) is selected from the group consisting of a
fluorophore and a radiolabel.
3 . The method according to claim 2, wherein the fluorophore is selected from the
group consisting of Hydrocoumarin, Methoxycoumarin, Alexa Fluor,
Aminocoumarin, Cy2, FAM, Alexa Fluor 488, Fluorescein FITC, Alexa Fluor 430,
Alexa Fluor 532, HEX, Cy3, TRITC, Alexa Fluor 546, Alexa Fluor 555, R-
phycoerythrin (PE), Rhodamine Red-X, Tamara, Cy3.5 581, Rox, Alexa Fluor 568,
Red 613, Texas Red, Alexa Fluor 594, Alexa Fluor 633, Allophycocyanin, Alexa
Fluor 633, Cy5, Alexa Fluor 660, Cy5.5, TruRed, Alexa Fluor 680, Cy7,
tetrachlorofluorescein (TET), SYBR green I or II, YBR Green II, SYBR Gold, YO
(Oxazole Yellow), TO (Thiazole Orange) and PG (PicoGreen).
4 . The method according to any one of the preceding claims, wherein the solid
phase coupled primer G (SP-primer) comprises a 5' linker sequence, supporting
coupling to the solid support.
5 5 . The method according to any one of the preceding claims, wherein the solid
phase coupled primer G (SP-primer) is coupled to a solid support selected from
the group consisting of a glass slide, a cover slip, COC (cyclic olefin copolymer),
COP (cyclic olefin polymer), PS (polystyrene), PC (polycarbonate), PMMA
(poly(methyl methacrylate)), PDMS (poly(dimethylsiloxane)), PET (poly(ethylene
10 terephthalate)), cellulose-based beads, sheet or paper, a glass bead, a polymeric
bead, a nanobead, a nanoparticle, graphene, an ELISA plate, and a polymeric
multiple well plate.
6 . The method according to any one of the preceding claims, wherein the LAMP
15 amplification mixture of step g) comprises at least one polymerase enzyme
supporting LAMP amplification and dinucleotide triphosphates (dNTPs).
7 . The method according to claim 6, wherein the polymerase enzyme, has strand
displacement activity.
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8 . The method according to claims 6 or 7, wherein the polymerase enzyme is
selected from the group consisting of Bst polymerase, Bst DNA Polymerase Large
Fragment, Bsm DNA Polymerase, Bsu DNA Polymerase Large Fragment, SD DNA
Polymerase, Deep VentR DNA Polymerase, Deep VentR TM (exo) DNA Polymerase,
25 DNA Polymerase I Large (Klenow) Fragment, M-MuLV Reverse Transcriptase,
Phi29 DNA Polymerase, VentR DNA Polymerase, VentR (exo) DNA Polymerase,
StrandDisplace Thermostable DNA Polymerase, and combinations thereof.
9 . The method according to any one of claims 6-8, wherein the LAMP amplification
30 mixture further comprises a reverse transcriptase, such as an AMV reverse
transcriptase.
10. The method according to any one of the preceding claims, wherein the
amplification steps are performed at a temperature in the range between 30-
35 75°C, such as 40-70°C, such as 50-65°C, or such as 55-65°C.
11. The method according t o any one of the preceding claims, wherein the target
sequence is single-stranded or double-stranded.
12. The method according t o any one of the preceding claims, wherein the target
sequence is DNA o r NA .
13. The method according t o any one of the preceding claims, wherein the sample
is selected from the group consisting of food (liquid/solid and semi solid), feed
(liquid/solid and semi solid), blood (serum, buffer coat, treated with heparin or
EDTA), tissue (paraffin embedded), tumor, biopsy, sputum, swabs (from both
human and animal), fecal (from both human and animal), water and waste-water
samples.
14. The method according t o any one of the preceding claims, wherein the target
sequence is of pathogenic origin, such as of bacterial, fungi o r viral origin, o r from
a gene involved in a disease.
15. The method according t o claim 14, wherein the target sequence originates
from a n organism selected from the group consisting of Salmonella spp,
Campylobacter jejuni , verotoxin producing Escherichia coli 0157: 1-17, Listeria
monocytogenes, Shigella dysenteriae, Avian Influenza Virus and Norovirus.
16. The method according t o any one of the preceding claims, wherein the target
sequence is a salmonella sequence.
17. The method according t o any one of the preceding claims, wherein the
immobilization region comprises an F2 region, complementary t o an F2C region.
18. The method according t o any one of the preceding claims, wherein the
method comprises providing a primer A (modFIP).
19. The method according t o claim 18, wherein the immobilization region of the
primer G is complementary t o a PIC region.
20. The method according to any one of the preceding claims, wherein the
method comprises primers for detection of multiple target sequences.
21. A kit comprising:
- Primers according to claim 1;
- An amplification mixture according to claim 6; and
- Optionally, instructions for detecting the presence or absence of a
defined target sequence using the primer set and amplification
mixture of the kit.
22. The kit according to claim 21, wherein primers for detection of multiple target
sequences are included.
23. The kit according to any one of claims 21 or 22, suitable for use in a lab-on-a-
chip (LOC) or lateral flow format.
24. Use of a kit according to any one of claims 21-23 for the detection of a target
sequence.
25. The use according to claim 24, wherein multiple targets are detected
simultaneously in a single sample.
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